Lin Elizabeth Yeu

Chief Medical Officer, Director · SEC CIK 1842190
Advertisement

Buy track record

How this insider's open-market purchases have performed
75%
of buys now in profit
3 up · 1 down
Avg return since buy+199.5%
Median return+272.6%
Best trade+280.8%
Worst trade−28.0%
Buys scored4
Average return by holding period — separates good entry timing from riding one long winner
After 1 month +2.3% 75% won · 4 trades
After 3 months −7.1% 25% won · 4 trades
After 6 months +15.1% 25% won · 4 trades
After 12 months +4.2% 25% won · 4 trades
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
Sep 21, 2023 STAA $40 $100K +704% +5.5% −18.2% −1.0% −22.9% −28.0%
Aug 15, 2023 TARS $17 $159.7K +149% −5.1% +5.5% +85.6% +58.6% +264.4%
Sep 14, 2022 TARS $16 $193K NEW +4.4% −7.9% −12.0% −9.3% +280.8%
Sep 14, 2022 TARS $16 $103.6K NEW +4.4% −7.9% −12.0% −9.3% +280.8%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 4 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$556.3K
4 trades
Open-market sells
$284.7K
5 trades
Net flow
+$271.6K
Net buying
Total filings
16
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
TARS
Sell Lin Elizabeth Yeu · Chief Medical Officer · Open-market sale · filed Mar 19, 2026 ΔOwn −1.6%

Lin Elizabeth Yeu sold $26.1K of TARS, trimming their stake 2%.

−$26.1K
390 sh @ $67
TARS
Sell Lin Elizabeth Yeu · Chief Medical Officer · Open-market sale · filed Dec 17, 2025 ΔOwn −8.7%

Lin Elizabeth Yeu sold $165.2K of TARS, trimming their stake 9%.

−$165.2K
2,078 sh @ $80
Advertisement
TARS
Sell Lin Elizabeth Yeu · Chief Medical Officer · Open-market sale · filed Jun 17, 2025 ΔOwn −12%

Lin Elizabeth Yeu sold $41.3K of TARS, trimming their stake 12%.

−$41.3K
1,006 sh @ $41
STAA
Buy Lin Elizabeth Yeu · Director · Open-market purchase · filed Sep 22, 2023 ΔOwn +704%

Lin Elizabeth Yeu, STAA's Director, spent $100K of their own money on 2,500 shares at $40, growing their stake 704%.

+$100K
2,500 sh @ $40
TARS
Buy Lin Elizabeth Yeu · Director · Open-market purchase · filed Aug 17, 2023 ΔOwn +149%

Lin Elizabeth Yeu, TARS's Director, spent $159.7K of their own money on 9,506 shares at $17, growing their stake 149%.

+$159.7K
9,506 sh @ $17
TARS
Buy Lin Elizabeth Yeu · Director · Open-market purchase · filed Sep 16, 2022 ΔOwn NEW

Lin Elizabeth Yeu, TARS's Director, spent $193K of their own money on 12,040 shares at $16, opening a brand-new position.

+$193K
12,040 sh @ $16
TARS
Buy Lin Elizabeth Yeu · Director · Open-market purchase · filed Sep 16, 2022 ΔOwn NEW

Lin Elizabeth Yeu, TARS's Director, spent $103.6K of their own money on 6,360 shares at $16, opening a brand-new position.

+$103.6K
6,360 sh @ $16

Frequently asked questions

What stock has Lin Elizabeth Yeu been buying?

Every open-market purchase (SEC code P) Lin Elizabeth Yeu has disclosed is in the feed above, newest first, with the ticker, share count, and dollar value. The scorecard nets these against sales and tracks how the buys have performed.

Where can I see Lin Elizabeth Yeu's Form 4 filings?

All of Lin Elizabeth Yeu's Form 4 transactions are listed above, each traceable to the original SEC EDGAR filing via the link on this page. Form 4 discloses insider buys and sells within two business days of the trade.

How is Lin Elizabeth Yeu's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from Lin Elizabeth Yeu's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.